With the field moving toward clinical breakthroughs and reaching new levels of maturity, you need reliable partners with reliable solutions, now more than ever, that are relevant to your line of work.
At Stem Genomics, we have been supporting scientists working with iPSCs through innovative QC solutions since 2018. This breadth of experience working alongside labs around the world has given us invaluable insight to better serve your needs today.
Early detection of 93% of the recurrent abnormalities found in hPSCs
One of the best demonstrations of this expertise translated into a concrete solution is our flagship assay, the iCS-digital™ PSC-28 probe. A great in-process solution, the iCS-digital™ PSC-28 probe test enables scientists to check for genomic abnormalities every 5 to 10 passages (Assou et al., 2020; McIntire et al., 2020; Pamies et al., 2017) at a fraction of the cost of most karyotyping solutions. Fast, cost-effective, and highly sensitive, it is the perfect complement to G-Banding. Indeed, its sensitivity and detection power enable it to capture <93% of the most recurrent abnormalities in hPSCs! In particular, it efficiently detects the sub karyotyping 20q11.21 abnormality that represents 22.9% of the recurrent structural variants identified in hPSCs (Assou et al., 2020).
Raising the bar to meet increasingly demanding standards
As part of our continuous commitment to scientific excellence, we have raised the bar on this assay in order to meet increasingly demanding standards.
We have integrated a second independent housekeeping gene into our protocol for the normalization of the assay. This dual-reference approach further strengthens result robustness and accuracy, in full compliance with the rigorous MIQE and ISO 20395 standards.
This advancement builds on the already reliable single-reference gene design and brings an additional layer of precision, particularly for highly variable samples where biological heterogeneity – such as rare mutations, gene editing events, or chromosomal instabilities – may occasionally influence normalization. In practice, this refinement will ensure optimal measurement stability across all contexts.
By combining two independent reference loci, this new version effectively decreases residual technical fluctuations and further reduces false-positive signals in critical genomic regions, delivering an even higher level of confidence in your results.
This is part of our commitment to you for continuous improvement.
And that’s not all!
What’s more, our recent acquisition by the Clean Cells group is expanding our capabilities. We are working together to meet your standards, and soon we will deliver a full analytical continuum from bench to clinic, with GMP-certified solutions.
Watch your space for more to come!